



March 4, 2014

## Ophthotech to Host R&D Day on March 7, 2014

-Webcast to Begin at 8:30 a.m. Eastern time-

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Friday, March 7, 2014, beginning at 8:30 a.m. ET. A panel featuring leading retinal specialists will discuss the company's expanded clinical programs for Fovista™ anRDRGF therapy in combination with anti-VEGF drugs for wet AMD. In addition, an update on Zimura™, an inhibitor of complement factor C5 for the dry and wet forms of AMD, will also be provided.

The live and archived webcast can be accessed through the Investor section of the Company's website at [www.ophthotech.com](http://www.ophthotech.com). To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start. The archived webcast will remain available on the Company's website for fourteen days following the call.

### About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista™ anRDRGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF drugs that represent the standard of care for the treatment of wet AMD. The Company's second product candidate Zimura™, an inhibitor of complement factor C5, is being developed for the treatment of dry and wet forms of AMD. For more information, please visit [www.ophthotech.com](http://www.ophthotech.com).

### Forward-looking Statements

*Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.*

### Investors

Ophthotech Corporation  
Kathy Galante, 212-845-8231  
Vice President, Investor Relations and Corporate Communications  
[kathy.galante@ophthotech.com](mailto:kathy.galante@ophthotech.com)

or

### Media

SmithSolve LLC on behalf of Ophthotech Corporation  
Jarrod Aldom, 973-442-1555 ext. 112  
[jarrod.aldom@smithsolve.com](mailto:jarrod.aldom@smithsolve.com)

Source: Ophthotech Corporation

News Provided by Acquire Media